SWK Holdings Corporation 9.00% Senior Notes due 2027 (SWKHL)
Oxford Ledge is still expanding full research coverage of SWKHL. A delayed quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
SWK Holdings provides specialty financing to life science companies through royalty purchases and debt investments in the sub-$50 million transaction market.
Source: 10-K (2025-12-31) · AI-generated analysis. Not investment advice. May contain errors.
SEC filings
- 8-K Entry into material agreement; Termination of material agreement; Completion of acquisition or disposition; Delisting / transfer of listing; 3.03; 5.01; Departure/election of directors or officers; Amendments to articles or bylaws; Financial statements and exhibits 2026-04-06
- 8-K Shareholder vote results 2026-03-31
- 10-K Annual financial report with audited statements 2026-03-20
- 8-K Creation of direct financial obligation 2026-02-13
- 8-K Creation of direct financial obligation; Financial statements and exhibits 2025-12-05
Source: SEC EDGAR.
Annual results
5 years of annual figures for SWKHL, as filed with the SEC. Figures are as reported and are not restated or adjusted.
| Fiscal year | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| 2025 | $41.5M | -$2.5M | -$0.21 |
| 2024 | $45.0M | $13.5M | $1.09 |
| 2023 | $37.8M | $15.9M | $1.25 |
| 2022 | $41.5M | $13.5M | $1.05 |
| 2021 | $56.2M | $25.9M | $2.02 |
Source: SEC EDGAR (XBRL company facts). Full statements and ratios in the terminal.
- Open SWKHL in the Oxford Ledge terminal — delayed quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.